|Bid||12.53 x 1400|
|Ask||14.26 x 1200|
|Day's Range||12.66 - 12.89|
|52 Week Range||9.14 - 19.48|
|Beta (3Y Monthly)||1.52|
|PE Ratio (TTM)||19.90|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Corcept (CORT) delivered earnings and revenue surprises of 38.89% and -0.34%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
If you're interested in Corcept Therapeutics Incorporated (NASDAQ:CORT), then you might want to consider its beta (a...
If you want to know who really controls Corcept Therapeutics Incorporated (NASDAQ:CORT), then you'll have to look at...
Looking at Corcept Therapeutics Incorporated's (NASDAQ:CORT) earnings update in March 2019, the consensus outlook from...
Biotech stocks came under pressure this week ahead of the ASCO 2019 presentations. Headlines on legal woes related to the opioid crisis and drug price manipulation led to weakness in some stocks. The unfolding ...
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...
Corcept (CORT) delivered earnings and revenue surprises of 11.11% and -3.96%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Menlo Park, California-based company said it had net income of 15 cents per share. Earnings, adjusted for non-recurring costs, were 20 cents per share. The drug developer posted revenue of $64.8 million ...
Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter. NASDAQ and Russell 2000 indices were already in correction territory. More importantly, Russell 2000 ETF (IWM) underperformed the larger S&P 500 ETF (SPY) by nearly 7 percentage points in the fourth quarter. Hedge funds and institutional […]
It hasn't been the best quarter for Corcept Therapeutics Incorporated (NASDAQ:CORT) shareholders, since the share price has fallen 20% in that time. But that scarcely detracts from the really solid long term returns gener...
Corcept's (CORT) Cushing's syndrome drug Korlym shows a steady progress. The company's efforts to expand the drug's label also hold promise and bode well for long-term growth.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Corcept Therapeutics Incorporated (NASDAQ:CORT) is a company with exceptional fundamentalRead More...
Corcept Therapeutics Inc. (CORT) is one of them. Warning! GuruFocus has detected 3 Warning Signs with CORT. With Corcept set to earn upwards of $1 per share in 2019, it is probably fairly valued at its current cap.
The most recent earnings update Corcept Therapeutics Incorporated's (NASDAQ:CORT) released in December 2018 indicated that the business endured a major headwind with earnings deteriorating by -42%. Below, I've presented keyRead More...